MGNX
What one share of Macrogenics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer. We generate our pipeline of product candidates from our proprietary suite of antibody technology platforms.
Macrogenics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.76 |
|---|---|
| Profit | −$0.23 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$1.03 |
| Cash and investments | $1.79 |
| Book value | $0.67 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $2.65 | −$1.69 | $0.33 | −$1.59 | — | $7.71 |
| 2017 | $4.37 | −$0.54 | $0.81 | −$0.42 | — | $8.12 |
| 2018 | $1.47 | −$4.19 | $0.61 | −$4.35 | — | $5.73 |
| 2019 | $1.33 | −$3.16 | $0.09 | −$2.88 | — | $4.71 |
| 2020 | $2.00 | −$2.47 | $0.11 | −$2.25 | — | $5.26 |
| 2021 | $1.29 | −$3.37 | $0.10 | −$2.50 | — | $3.91 |
| 2022 | $2.47 | −$1.95 | $0.06 | −$1.47 | — | $2.30 |
| 2023 | $0.95 | −$0.15 | $0.03 | −$1.29 | — | $2.46 |
| 2024 | $2.39 | −$1.07 | $0.06 | −$1.15 | — | $1.85 |
| 2025 | $2.37 | −$1.18 | $0.03 | −$1.31 | — | $0.88 |